Ischemix is developing novel cytoprotective compounds to prevent and treat serious diseases/conditions. The initial focus of the Company has been prevention of hospital-acquired kidney injury (HA-AKI) and cardiac injury associated with PCI. CMX-2043 is also currently conducting additional preclinical development to confirm initial studies that showed efficacy of the drug for treatment of traumatic brain injury.
Ischemix has selected HA-AKI as a target indication because:
The patient populations that contribute the largest number of HA-AKI diagnoses in the US annually are:
|Population Description||Annual Frequency||Est. Incidence of HA-AKI|
|Intensive care unit patients||5,000,000||16-67%|
|Diagnostic cardiac catheterizations – higher-risk||400,000||25-30%|
|Diagnostic cardiac catheterizations – lower-risk||600,000||5%|
|Coronary artery bypass surgeries||400,000||5-30%|
Ischemix has selected periprocedural cardiac injury as a target indication because:
Global patient populations susceptible to periprocedural cardiac injury:
Frequency and estimated resulting periprocedural cardiac injury in the US annually is:
|Population Description||Annual Frequency||Est. Incidence of
Type 4(a) MI
|Therapeutic cardiac catheterization (PCI)||600,000||up to 16%|
|Coronary artery bypass surgery (CABG)||400,000||up to 20%|
Percutaneous coronary intervention (PCI) is a common procedure in which a balloon is inserted into a blood vessel to repair an obstruction and a stent is inserted to keep the blood vessel from re-occluding. In a CABG procedure, a new blood vessel is connected from the aorta to the coronary artery to bypass the blocked section of the coronary artery and improve the blood supply to the heart. The most common periprocedural injury during the PCI and CABG is myocardial infarction.
In addition to HA-AKI, other forms of acute kidney injury occur outside the hospital each year due to trauma (principally automobile accidents), the ingestion of ethylene glycol or carbon tetrachloride, and overdoses of acetaminophen and other nephrotoxic substances. Ischemix intends to evaluate the use of CMX-2043 or its analogs as a treatment for CA-AKI from these causes.